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Glucose Derivative Induced Vasculopathy in 
Children on Chronic Peritoneal Dialysis
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Georg Hildenbrand , Bradley A. Warady, Franz Schaefer, Sotirios G. Zarogiannis , Klaus Kratochwill ,* Claus Peter Schmitt *
RATIONALE: Patients with chronic kidney disease (CKD) have an exceedingly high cardiovascular risk; which further increases 
in patients on peritoneal dialysis (PD). The pathophysiological role of reactive metabolites accumulating in CKD such as 
glucose degradation products (GDP) is uncertain.
OBJECTIVE: Delineating the impact of GDP present in PD fluids in accelerated vasculopathy development in patients 
with CKD.
METHODS AND RESULTS: Omental and parietal peritoneal tissues were obtained from 107 children with CKD before dialysis 
and 90 children on chronic PD with PD fluids containing very low or high concentrations of GDP. Omental arterioles, 
protected from local PD fluid exposure by surrounding fat, were microdissected for multiomics analyses. High-GDP 
exposed omental arterioles exhibited 3-fold higher advanced glycation endproduct concentrations and upregulated 
genes involved in cell death/apoptosis and suppressed genes related to cell viability/survival, cytoskeleton organization, 
and immune response biofunctions. Vasculopathy-associated canonical pathways concordantly regulated on gene 
and protein level with high-GDP exposure included cell death/proliferation, apoptosis, cytoskeleton organization, 
metabolism and detoxification, cell junction signaling, and immune response. Parietal peritoneal arterioles of patients 
exposed to high-GDP fluids exhibited lumen narrowing compared to patients with CKD stage 5 (end-stage kidney 
disease) and patients on low-GDP PD, intima thickness was increased. Protein quantification verified increased 
proapoptotic activity and cytoskeleton disintegration, single-molecule-localization microscopy demonstrated arteriolar 
endothelial ZO-1 (zonula occludens-1) disruption. Absolute and per endoluminal surface length, arteriolar endothelial 
cell counts inversely correlated with GDP exposure, caspase-3, TGF (transforming growth factor)-β–induced pSMAD2/3 
(phosphorylated SMAD2/3), interleukin-6, ZO-1 abundance, and lumen narrowing. In vitro, 3,4-dideoxyglucosone-3-ene 
reduced lamin-A/C and membrane ZO-1 assembly, increased pSMAD2/3, and ionic and 4 and 10 kDa permeability of 
arterial endothelial cells.
CONCLUSIONS: Our findings indicate a fundamental role of GDP in PD-associated vasculopathy, exerted by endothelial cell 
junction and cytoskeleton disruption, and induction of apoptosis. They should redirect the focus of research and intervention 
on targeting reactive metabolite overload in CKD and PD.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01893710.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
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Cardiovascular disease is the leading cause of death worldwide.1 Chronic kidney disease (CKD) is increasingly common due to the increasing preva-
lence of risk factors, such as obesity, hypertension, and 
diabetes mellitus and potentiates the cardiovascular 
risk. In dialysis patients, cardiovascular risk is particu-
larly high, 40× higher than in the age-matched general 
population.2 The role of reactive metabolites accumulat-
ing in CKD is uncertain.
The chronic administration of dialysis fluids in 
peritoneal dialysis (PD) patients provides a unique 
diagnostic window and research tool. Conventional 
PD fluids (PDF) contain high concentrations of glu-
cose and high concentrations of glucose degradation 
products (GDP) generated during the heat steriliza-
tion process and prolonged storage. Following infu-
sion into the peritoneal cavity, the acidic pH is rapidly 
equilibrated3 and GDP are rapidly absorbed into the 
circulation and increase systemic concentrations of 
advanced glycation end products (AGE).4,5 Separating 
glucose at a very low pH from the electrolytes and 
buffer compounds in double-chamber PD fluid bags 
largely prevents GDP formation and the associated 
systemic GDP load.6–8 The impact of the PD-associ-
ated GDP load on cardiovascular health is unknown. 
Nonstandard Abbreviations and Acronyms
3,4-DGE 3,4-dideoxyglucosone-3-ene
AGE advanced glycation end products
Casp3 caspase-3
CKD chronic kidney disease
CKD5  CKD stage 5 (end-stage kidney 
disease)
CLDN1 claudin-1
GDP glucose degradation products
IL interleukin
L/V lumen/vessel




RAGE  receptor for advanced glycation end 
products
ST2 suppressor of tumorigenicity 2
TGF transforming growth factor




• Chronic kidney disease is increasingly common and 
potentiates the cardiovascular risk, with a 40× higher 
risk in dialysis patients as compared to the age-
matched general population.
• Peritoneal dialysis (PD) fluids contain various amounts 
of glucose degradation products (GDP), which are rap-
idly absorbed.
What New Information Does This Article Pro-
vide?
• In children on PD with high-GDP exposure, advanced 
glycation endproduct deposition is increased in omen-
tal arterioles protected from direct PD fluid exposure.
• Vascular disease–associated canonical pathways are 
concordantly regulated in arterioles on a gene and pro-
tein level with high-GDP exposure associated with cell 
death/proliferation, apoptosis, cytoskeleton organiza-
tion, metabolism and detoxification, cell junction signal-
ing, and immune response.
• Peritoneal arteriolar endothelial cell number is reduced 
with increased dialytic GDP exposure and arteriolar 
vessel lumen reduced due to intima thickening.
Patients on dialysis have an exceedingly high car-
diovascular risk, the impact of reactive metabolites is 
debated. Conventional PD fluids contain high amounts 
of GDP, while GDP formation is largely prevented in 
costly double-chamber PD fluids. In omental arterioles 
from children with underlying diseases limited to kidney 
dysfunction and devoid of lifestyle factors, we demon-
strate a 3-fold higher advanced glycation end product 
accumulation with high-GDP PD treatment. Multiomics 
analyses revealed activation of cell death and apopto-
sis pathways and suppression of cell viability/survival, 
cytoskeleton organization, and immune response bio-
functions. In peritoneal arterioles endothelial number 
per endoluminal surface length is inversely related with 
GDP exposure, intima thickness is increased. Key pro-
tein quantifications verify increased proapoptotic activity 
and cytoskeleton disintegration; tissue single-molecule-
localization microscopy demonstrates GDP-related 
reduced clustering of endothelial zona occludens-1 pro-
tein, which links the actin cytoskeleton to inter-endothe-
lial junctions. In vitro studies reconfirm dose-dependent 
endothelial barrier disruption by GDP. Our findings chal-
lenge the use of PD fluids containing GDP and should 
redirect the focus of research on strategies to preserve 
endothelial integrity and barrier function in patients with 
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Most clinical trials failed to provide evidence for an 
improvement of relevant clinical outcomes, such as 
peritonitis incidence, PD technique outcome, cardio-
vascular health, and patient survival.9
Children are uniquely suited to study the patho-
physiological mechanisms of vasculopathy since they 
are virtually devoid of aging and lifestyle-related fac-
tors, such as smoking, and the underlying diseases 
in the majority of cases are limited to the kidney and 
do not affect the vascular integrity. Studying omen-
tal arterioles is of particular interest because together 
with small arteries, they represent key segments of the 
vascular tree defining blood pressure.10 Surrounded by 
fat tissue they are protected from immediate PD fluid–
induced effects. Thus, these arterioles reflect vascu-
lar pathophysiology induced by CKD and by systemic 
PD–induced toxicity. Blood glucose concentrations 
remain in the physiological range in children on PD, 
disturbed glucose homeostasis, or diabetes mellitus 
are rarely observed.11 The underlying pathomecha-
nisms of systemic vasculopathy induced by CKD and 
PD-associated systemic toxicity have not yet been 
comprehensively assessed. We, therefore, analyzed 
omental arterioles and parietal peritoneal tissues 
obtained from pediatric patients with end-stage CKD 
either immediately before dialysis (CKD stage 5 [end-
stage kidney disease; CKD5]) or after exposure to PD 
with fluids containing low and high concentrations of 
GDP by digital histomorphometry, transcriptomics, and 
proteomics. Key molecular findings were validated in 
the parietal peritoneal arterioles of matched patient 
subcohorts and in vitro.
METHODS
Data Availability
All materials and methods of this study are described in detail 
in the Data Supplement, please also see for Major Resources 
Table in the Data Supplement. Most relevant details are given 
here. The supporting data are available from the corresponding 
author upon request.
Study Population
The International Peritoneal Biobank comprises peritoneal tis-
sue according to a standardized protocol from children at the 
time of Tenckhoff catheter insertion (CKD5) and on chronic 
PD. In patients on PD, the sampling site was at least 5 cm 
distant from the PD catheter entry site. Institutional review 
boards of the 27 participating centers approved the study. 
Written informed consent was obtained from parents and 
patients as appropriate. The study was performed according 
to the Declaration of Helsinki. None of the children selected 
were overweight (>85th height age-related body mass index 
percentile). After matching for age, glucose exposure, and 
PD duration, parietal peritoneal tissue of 60 double-chamber, 
low-GDP and 30 single chamber, high-GDP PD fluid–treated 
patients were selected and age-matched to 107 children with 
CKD5. Individual GDP exposure was calculated from the 
actual PD regime and GDP content of the administered PD, 
as published previously.7,8 Treatment details are given in the 
Data Supplement.
Molecular mechanisms of vasculopathy were studied 
in omental arterioles in the CKD5, low-GDP PD, and high-
GDP PD groups. Arterioles were microdissected from the 
surrounding fat tissue. mRNA and protein were isolated for 
transcriptome and proteome analysis (n=8 in CKD5, n=6 for 
high-GDP, and n=5 for low-GDP group). These children were 
matched for age, had noninflammatory underlying diseases, 
and no history of peritonitis, transplantation, or immunomodu-
latory therapy. PD patients were moreover matched for dialytic 
glucose exposure and PD duration.
For validation of the key molecular pathways identified 
by cross-omics in arterioles, parietal peritoneal tissue of 10 
patients with low- and high-GDP PD fulfilling the same selec-
tion criteria as the omics cohort underwent digital immunohis-
tochemistry analyses.
Transcriptome Analysis
Omental mRNA was isolated (RNAeasy; Qiagen, Hilden, 
Germany) and concentration and quality were determined. A 
total of 2.5 ng of mRNA with RNA integrity number >7 per 
sample were analyzed using Illumina Human Sentrix Beads 
microarray (Illumina, SanDiego) and scanned on iScan array 
scanner. Data import, extraction, background correction, nor-
malization, and differential abundance analysis were done with 
R (http://www.r-project.org/) packages (illuminaHumanv4.db, 
beadarray, neqc, arrayWeights, and LIMMA). Raw data were 
submitted to ArrayExpress (http://www.ebi.ac.uk/arrayex-
press) under the accession E-MTAB-9646.
Proteome Analysis
Protein concentrations and sample quality were assessed 
by SDS-PAGE. Filter-aided sample preparation and label-
ing of peptides with isobaric mass tags (TMT 11-plex, 
Thermo Fisher Scientific, Waltham, MA) were performed 
as described before.12 Two-dimensional liquid chromatog-
raphy was performed by reverse-phase chromatography at 
high and low pH. Mass spectrometry scans were performed 
on a QExactive (Thermo Fisher) liquid chromatography–
mass spectrometry settings and raw data processing are 
described in detail in the Methods in the Data Supplement. 
Raw liquid chromatography–mass spectrometry data were 
submitted to PRIDE (Proteomics Identification Database) 
(https://www.ebi.ac.uk/pride/) under the accession 
PXD021747.
Pathway Analysis
Significantly regulated genes and proteins were submit-
ted to analysis of enriched pathways, diseases, and biofunc-
tions using the Ingenuity Pathway Analysis software (Qiagen, 
Hilden, Germany). Significantly enriched diseases and biofunc-
tions with an activation Z score >1 or < −1 (cutoff P<10-5 
on the transcription level and cutoff P<10-3 on the protein 
level) were extracted and clustered according to shared genes. 
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of the significantly regulated transcripts and proteins in vas-
culopathy. Vasculopathy-associated genes (n=2460) were 
extracted from Ingenuity Pathway Analysis and overlapped 
with significantly regulated transcripts and proteins. Pathways 
involved in vasculopathy were clustered according to shared 
genes. Pairwise similarity data (edges representing shared 
genes) were generated using R and visualized using Cytoscape 
3.8.0 (www.cytoscape.org).
Tissue Immunohistochemistry
Histological stainings were performed according to stan-
dard methods. Parietal peritoneal arterioles of 60 to 100 µm 
diameter (5–7 per section) were analyzed. Stained sections 
at ≥5 different sites were analyzed for submesothelial thick-
ness. Separate analyses of specific proteins in the mesothelial 
and submesothelial area did not reveal significant differences 
between the groups; therefore, total peritoneal data are given. 
For specific stainings, scanning, digital image analyses, and cal-
culations, see expanded methods section.
Single-Molecule Localization Microscopy Data 
Analysis
The single-molecule localization microscopy microscope setup 
is described in expanded methods. The recorded single-mole-
cule localization microscopy data were analyzed with in-house 
Python scripts, corresponding to MATLAB-based software 
described previously.13,14 To reduce noise, a threshold of 3 was 
used and the first 30 frames of each stack were discarded.
The programs detect the position of the blinking dye mol-
ecules, use a 2-dimensional gaussian to calculate their posi-
tion, and compile a matrix containing the signal amplitude, the 
x, y coordinates and the corresponding errors. Based on this 
matrix, relative distance distribution histograms (0–100 nm), 
signal-count boxplots, and pointillistic images of the vessels 
were created. The recorded images were manually sorted by 
blood vessel size to include only arterioles in the analysis.
For in vitro studies see extended methods.
Statistics
Descriptive data were summarized using proportions, means 
(SD), or medians (interquartile range). Normal distribution was 
assessed graphically and by Shapiro-Wilk test, Pearson, or 
Spearman correlations were calculated as appropriate.
T test or Mann-Whitney test were applied for testing of dif-
ferences between 2 groups based on the data distribution. For 
describing differences in proportions, χ2 or Fischer exact test 
were used. Two-sided tests were applied unless stated other-
wise. One-sided tests were used only in the validation cohort 
(n=10 per group) to confirm direction of regulation from com-
parison of 30 versus 60 patients for submesothelial thickness, 
microvessel density, blood vessel density, and lumen/vessel 
(L/V) ratio, which were significantly regulated. One-way para-
metric ANOVA as well as nonparametric Kruskal-Wallis was 
implemented for multiple group comparisons, with Holm-Sidak 
and Dunn methods, respectively, to adjust for multiplicity. For 
single-molecule localization microscopy cluster analysis and 
for ionic and solute permeability measurement, 2-way ANOVA 
followed by Holm-Sidak test was applied. GraphPad Prism 8 
software (La Jolla) was used.
RESULTS
Omental Arteriolar Pathway Regulation With 
High-GDP Exposure
GDP-related systemic vascular effects were studied in 
omental arterioles microdissected from the surrounding 
fat from patients with CKD5 and on PD with low- and 
high-GDP fluids (Figure 1). Biochemical findings were 
not statistically different, as was the PD treatment in the 
PD groups (Table I in the Data Supplement). The arte-
riolar lumen/vessel (L/V) ratio was 0.58 (0.53–0.62) 
in CKD5, 0.59 (0.50–0.62) in patients with high-GDP, 
and 0.55 (0.50–0.61) in patients with low-GDP fluid 
exposure (P=0.72). Omental arteriolar AGE deposition 
was increased 3-fold with high compared with low-GDP 
exposure (12% [7.9–13.9] versus 1.5% [0.9–5.8] posi-
tive arteriolar area; P=0.043).
The arterioles underwent transcriptome and pro-
teome analyses. Transcripts mapping to 11 920 genes 
as well as 3611 identified proteins (not counting pro-
teins that were identified with only a single peptide) 
were quantified. Compared with CKD5, high-GDP 
exposure induced transcripts associated with 684 
arteriolar genes and 137 proteins and suppressed 
1560 genes and 55 proteins, whereas low-GDP expo-
sure resulted in upregulation of only 145 transcripts 
and 110 proteins and downregulation of 38 transcripts 
and 34 proteins, respectively (raw P values, cutoff 
α=0.01; Figure I and Excel File I in the Data Supple-
ment). Compared to CKD5, arteriolar exposure to low-
GDP concentrations had a smaller effect (183/144 
regulated transcripts/proteins) than high-GDP expo-
sure (2244/192 regulated transcripts/proteins).
Directly comparing high- to low-GDP exposure 
yielded 2162 arteriolar transcripts (cutoff P<0.01, Fig-
ure 2A) associated with enriched activated diseases and 
biofunctions related mainly to cell death and apoptosis 
(66 functions with activation Z scores up to 10.4; cut-
off P<10-5) and deactivated functions related to orga-
nization of cytoskeleton, cell migration and cell survival 
and viability (155 functions; activation Z scores down to 
−8.0; Table II in the Data Supplement). Enriched func-
tions (n=99) strongly activated or inactivated (Z score 
above 2.0 or below −2.0) were visualized according to 
shared genes, applying a minimum gene overlap of 20% 
for shown edges in the network (Figure 3A). On the pro-
tein level, the same cutoff of P<0.01 yielded 351 pro-
teins (Figure 2B) with enriched activated diseases and 
biofunctions related to infection, lipid, and carbohydrate 
metabolism (75 functions; activation Z scores up to 3.9) 
and suppressed organismal survival and injury (31 func-
tions; activation score down to −3.2).
The considerable overlap between the proteome 
and transcriptome, comprising 2713 unique gene 
names, confirmed the high quality of both experiments 
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the transcriptome analysis (n=846) were significantly 
enriched for membrane-associated lipoproteins, as well 
as for mitochondrial, nuclear body, and extracellular 
proteins. Transcripts not detected on the protein level 
(n=9206) were significantly more associated with low 
abundance genes, such as transcription factors, as well 
as intracellular and histone-associated genes (Excel File 
II in the Data Supplement).
Cross-omics analysis revealed 223 enriched (cutoff 
P<0.01) pathways on the transcriptomics or proteomics 
level (Excel File III in the Data Supplement). These were 
subsequently annotated with additional information on 
genes associated with vasculopathy in the Ingenuity 
Pathway Analysis knowledge base, clustered according 
to shared genes and visualized as a network (Figure 3B). 
Concordant differential regulation of vasculopathy-
related canonical pathways associated with cytoskeleton 
organization, cell junction signaling, (glucose) metabo-
lism and detoxification, cell death/proliferation and apop-
tosis, as well as immune response pathways.
Figure 1. Overview on patient cohorts, tissues studied, and methods applied.
Omental arterioles from patients using peritoneal dialysis (PD) fluids with low–glucose degradation products (GDP) and high-GDP 
concentrations, respectively, were microdissected from the surrounding fat (preventing direct PD fluid exposure) and underwent 
multiomics analyses. Key findings were validated in submesothelial parietal peritoneal arterioles, exposed to GDP and high glucose 
concentrations. Methodologies and analytic approach are depicted in the lower parts. AGE indicates advanced glycation end products; 
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GDP Aggravates Parietal Peritoneal 
Vasculopathy and Fibrosis and Suppresses 
Angiogenesis
Parietal peritoneal tissues obtained from children with 
CKD5, low- and high-GDP PD, matched for age, PD 
duration, and dialytic glucose exposure, were analyzed 
by digital histomorphometry (Table III in the Data Supple-
ment, Figure 1). Children treated with high-GDP fluid 
had developed more severe vasculopathy as indicated 
by a lower L/V ratio of parietal peritoneal arterioles and 
more pronounced submesothelial fibrotic thickening. 
Microvessel density was higher with low-GDP compared 
to high-GDP PD (Table 1). Lymphatic vessel density as 
quantified by podoplanin staining was 2-fold higher with 
high- versus low-GDP fluid exposure, diffuse podoplanin 
staining 3-fold more prevalent, generalizing a finding 
previously reported in patients with encapsulating peri-
toneal sclerosis.15
In multivariable analysis adjusting for PD fluid type, 
PD duration, glucose exposure, and the history of 
peritonitis, high-GDP PD usage was associated with 
increased vasculopathy and submesothelial fibrosis and 
lower microvessel density. The degree of submesothelial 
fibrosis also depended on the PD duration but to a much 
smaller extent than on GDP exposure (Table IV in the 
Data Supplement). Findings were gender independent.
Parietal Peritoneal Validation Studies
For quantitative cross-validation of omental arteriolar 
findings in parietal peritoneal arterioles, subgroups of 
children were selected applying the same rigorous crite-
ria as for the arteriolar omics analysis. Biochemical find-
ings were not statistically different, and daily total GDP 
exposure was 4× higher with high-GDP exposure (Table 
V in the Data Supplement). Histomorphometric findings 
of the primary cohort (Table 1) were reconfirmed. Vas-
culopathy was more severe with high-GDP exposure, 
ie, L/V ratio was lower, due to a higher intima thickness 
(Figure 4A), whereas media thickness and external ves-
sel diameter were not statistically different between 
groups (Figure 4B, Table 2). Intima thickness correlated 
with GDP exposure (r=0.47, P=0.042). No vascular 
microcalcifications were detected. Submesothelial fibro-
sis was more pronounced, blood and lymphatic vessel 
density were reduced (Table 2), and inflammatory cell 
infiltration was lower with high-GDP PD.
GDP Induce Arteriolar Endothelial Apoptosis
Arteriolar omics analyses demonstrated marked acti-
vation of apoptosis pathways with high-GDP exposure 
(Figure 3). Similar to omental arterioles, AGE accumu-
lation was higher in parietal peritoneal arterioles with 
high-GDP PD (P=0.062) and correlated to individual 
GDP and 3,4-dideoxyglucosone-3-ene (3,4-DGE) 
exposure (r=0.71/0.67, P=0.00032/0.0011; Table 3). 
The AGE receptor, RAGE, correlated with AGE abun-
dance (r=0.38, P=0.078). Limiting the analysis to the 
arteriolar endothelium reconfirmed high-GDP exposure 
induced AGE deposition (P=0.0041), and Casp3 (cas-
pase 3), p16 (cyclin-dependent kinase inhibitor 2A), 
and pSMAD2/3 upregulation (P=0.029, P=0.026, and 
P=0.020 compared with low-GDP exposure).
The structural protein of the nuclear envelope, lamin-
A/C, was lower in omental arterioles on transcript and 
protein levels with high-GDP exposure and concordantly 
lower in peritoneal arterioles (Table 3, Figure 4C). Cleaved 
Casp3, a marker of apoptosis induction (Figure 4D), and 
Figure 2. Regulation of omental arteriolar transcriptome and proteome.
Differentially regulated transcripts (A) and proteins (B) obtained from arterioles exposed to high–glucose degradation products (GDP; n=6) and 
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Figure 3. Network of enriched diseases and biofunction identified by transcriptomics and Network visualization of enriched 
vasculopathy-associated canonical pathways.
Network of diseases and biofunctions enriched in arterioles exposed to high–glucose degradation products (GDP) concentrations (n=6) as compared 
to arterioles exposed to low-GDP concentrations (n=5) are visualized according to shared genes, applying a minimum gene overlap of 20% for shown 
edges in the network. Ninety-nine strongly activated or inactivated (Z score above 2.0 or below −2.0) functions were included. Red circles indicate 
gene upregulation, and blue circles indicate downregulation (A). B, Respective enriched vasculopathy-associated canonical pathways (n=223) on 
transcriptomics or proteomics level annotated with information on vasculopathy-associated genes and clustered according to shared genes. AMPK 
indicates 5' adenosine monophosphate-activated protein kinase; DARPP32, dopamine- and cAMP-regulated neuronal phosphoprotein; ILK, integrin-
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p16, a cell cycle arrest marker, were more abundant. 
Arteriolar AGE (r=0.62, P=0.0053), RAGE (r=0.55, 
P=0.014), Casp3, and p16 were correlated with IL 
(interleukin)-6 (r=0.40, r=0.71 and P=0.087, P=0.0011).
Both in absolute numbers and expressed relative to 
endoluminal surface length, the endothelial cell number 
was 40% and 23% lower in peritoneal arterioles from 
patients with high-GDP exposure. Also, endothelial cir-
cumference was lower (Table 2, Figure 4E), whereas the 
external arteriole diameter was not statistically different 
in both groups. The number of endothelial cells corre-
lated with the L/V ratio (r=0.46, P=0.043), inversely with 
GDP exposure (r=−0.51, P=0.020, Figure 4F), AGE 
and RAGE (r=−0.41 and −0.71, P=0.072 and 0.0011), 
Casp3 (r=−0.48, P=0.038), IL-6 (r=−0.57, P=0.011), 
pSMAD2/3 (r=−0.49, P=0.054), ZO-1 (zonula 
occludens-1; r=−0.51, P=0.025), and p16 (r=−0.56, 
P=0.012). The relative endothelial cell number per µm 
endoluminal surface length correlated inversely with 
GDP exposure, with AGE, RAGE, IL-6, and p16 abun-
dance (r=−0.51, r=−0.44, r=−0.68,r=−0.58, r=−0.54; 
P=0.025, P=0.056, P=0.0010, P=0.0093, P=0.016).
RAGE activation induces TGF (transforming growth 
factor)-β–SMAD signaling,16 which is involved in the 
development of vasculopathy.17,18 TGF-β downstream 
effector pSMAD2/3 was more abundant in parietal peri-
toneal arterioles with high-GDP exposure (P=0.06) and 
correlated with AGE/RAGE (r=0.62, P=0.0039/r=0.54, 
P=0.018), p16 (r=0.61, P=0.0062), and IL-6 abundance 
(r=0.68, P=0.0014, Table 3).
GDP-Induced Arteriolar Cytoskeleton and Tight 
Junction Disintegration
The arteriolar omics analysis demonstrated high-GDP 
exposure–related suppression of canonical actin cytoskel-
eton and tight junction pathways (Figure 4, Table II in the 
Data Supplement). Immunostaining demonstrated upreg-
ulation of the actin depolymerase Myo-1B (myosin1B) 
in peritoneal arterioles exposed to high-GDP, whereas 
no difference was observed for actin-binding protein 
profilin. ZO-1 connects intercellular junction proteins to 
the cytoskeleton and is involved in inflammation,19 apop-
tosis,20 and early vasculopathy.21,22 Peritoneal arteriolar 
Table 1. Histomorphometric findings of children with CKD5 and of children treated with high or low GDP PD.
 
CKD5 High-GDP PD Low-GDP PD P value
P value (high vs 
low)(n=107) (n=30) (n=60)  
Age, y 8.6±6.0 8.54±5.3 8.3±5.7 0.97* 0.88*
Gender (male/female) 67/40 18/12 29/31 n.a. n.a.
BMI 16 (15–18) 17 (15–20) 17 (16–18) 0.46† 0.93†
PD duration, mo n.a. 18 (7–25) 14 (7–29) n.a. 0.81†
Peritonitis [% patients with history of perit.] n a. 28% 38% n.a. 0.47‡
Glucose exposure, g (m2·d) n a. 86.0±50.1 94.2±33.7 n.a. 0.39*
Total GDP exposure, µmol/(d·m2) BSA n.a. 1490 (1078–1833) 138 (98–461) n.a. 1.0×1015†
3,4-DGE exposure, µmol (d·m2) BSA n.a. 72.6 (59.2–84.8) 5.8 (4.3–40.0) n.a. 6.9×109†
L/V ratio 0.48±0.11 0.35±0.11 0.42±0.13 0.001* 0.016*
Mesothelial cell coverage (0–6) 4.1±1.7 2.6±2 2.2±2.1 7.4×1010* 0.32*
Submesothelial thickness, µm 292±118 622±288 417±209 3.0×1015* 13×106*
Total microvessel density, /mm2 152±111 149±109 216±162 0.005* 0.021*
Sub. microvessel number, /mm 40±29 89±82 90±88 8.8×107* 0.960*
Diffuse podoplanin staining [% of pos. pat.] 0% 46% 18% 1.9×1010‡ 6.0×103‡
Lymphatic vessel density, /mm2§ 39±29 14±8 32±28 n.a. n.a.‡§
Blood vessel density, /mm2§ 100 (49–153) 122 (36–245) 138 (67–253) 0.009† 0.13†
Blood vessel number, /mm§ 24 (13–41) 36 (23–93) 52 (22–81) 5.7×105† 0.61†
Total endothelial surface area, µm2/µm3§ 8.9 (5–15) 8.1 (5.2–17) 10.6 (6–18) 0.51† 0.46†
Lym. endothelial surface area, µm2/µm3§ 2.4±2 2.0±1.4 2.9±2.6 n.a. n.a.§
Blood vessel end. surface area, µm2/µm3§ 7.3 (3–13) 6.9 (2–16) 8.2 (3–11) 0.75† 0.48†
3,4-DGE indicates 3,4-dideoxyglucosone-3-ene; BMI, body mass index; CKD5, chronic kidney disease stage 5 (end-stage kidney disease); GDP, glucose degradation 
product; L/V, lumen/vessel; n.a., not applicable; and perit., peritonitis.
*ANOVA was applied for comparison of the 3 groups and followed by post hoc comparison of high- vs low-GDP PD groups with Holm-Sidak correction for multiple 
testing. Student t test was used for parameters not applicable in patients with CKD5.
†Kruskal-Wallis test was used, followed by post hoc comparison of high- vs low-GDP PD group with Dunn correction for multiple testing. Mann-Whitney test was used 
for parameters not applicable in patients with CKD5.
‡Fisher exact test.
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Figure 4. Arteriolar lumen narrowing and induction of arteriolar cell death pathways with high–glucose degradation products 
(H-GDP) peritoneal dialysis (PD).
Intima thickness is increased in patients with high-GDP exposure (A), media thickness (B) and external vessel diameter (see Table 2) are not 
statistically different. GDP/advanced glycation end product (AGE) induced apoptotic pathways in arterioles from H-GDP exposed patients. 
Lamin-A/C is suppressed (C) and Casp3 (caspase-3) induced (D) in parietal peritoneal arterioles from H-GDP patients, scale bars =50µm. 
Endothelial cell number per arterioles and per µm endoluminal surface length is reduced after H-GDP PD exposure (E) and (F) correlated with 
total GDP exposure (Spearman r=−0.51, P=0.020; G). n=10 per group, data are presented as median (interquartile range), Mann-Whitney test 
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ZO-1 abundance did not differ between the high- and 
low-GDP groups (Table 3) but correlated with the L/V 
ratio (r=−0.52, P=0.021), Casp3 (r=0.43, P=0.061), p16 
(r=0.54, P=0.016), and IL-6 (r=0.50, P=0.028).
Because endothelial integrity depends on the spa-
tial organization of the intercellular junctions, we per-
formed single-molecule localization microscopy of ZO-1. 
The spatial organization of the arteriolar endothelial 
ZO-1 molecules was analyzed according to Ripley dis-
tance frequency curve shapes. Peaks occurring in these 
curves indicate molecular cluster formation, a signa-
ture correlated to functionality of membrane-embedded 
molecules.23 The slope of the Ripley curves at higher 
distances reflect the degree of randomness of the sur-
rounding points.18 The degree of ZO-1 clustering in 
arteriolar endothelial cells was lower with high-GDP PD, 
suggesting less densely organized ZO-1 molecules in 
the junctional area (Figure 6A), the degree of random-
ness of the surrounding points was much higher. Most 
frequent distances between single ZO-1 molecules 
were higher with high-GDP compared with low-GDP 
exposure (92 [54.5–97] nm versus 34.5 [28.3–42] nm; 
P=6.1×10-9, Figure 6B). No difference was observed for 
the number of membrane-bound ZO-1 molecules per 
nm2 ([4.33±3.10] 10-6 and [4.68±3.65] 10-6 counts/
nm2, P=0.70; Figure 6C). Sealing junction CLDN1 (clau-
din-1) abundance in parietal arterioles was not statisti-
cally different between the groups but in arterioles with 
high-GDP exposure, correlated with L/V ratio (r=0.63, 
P=0.061), that is, inversely with vasculopathy.
Table 2. Peritoneal Morphology and Cellular Infiltration
 
 
High-GDP PD Low-GDP PD
P value(n=10) (n=10)
Age, y 2.8 (1.8–5.6) 4.9 (1.9–8.7) 0.35
Gender (male/female) 5/5 6/4 n.a.
BMI 17.4 (16.0–21.2) 16.9 (13.9–18.4) 0.46
PD duration, mo 18.5 (5.4–25) 11.5 (6.3–16.5) 0.45
Glucose exposure, g/(m2·d) 138 (101–159) 125 (94–147) 0.28
Total GDP exposure, µmol/(d·m2) BSA 1846 (1358–1982) 171 (143–900) 4.1×104*
3,4-DGE exposure, µmol (d·m2) BSA 70.9 (50.6–75.5) 7.0 (5.9–55.7) 0.027*
L/V ratio 0.45 (0.34–0.50) 0.52 (0.46–0.59) 0.042*
No. of endothelial cells per arteriole 6 (5.4–7.4) 9.3 (8.4–10.2) 6.9×104*
Endothelial cells/µm 3.8 (3.4–4.4) 4.7 (4.2–5.3) 6.8×103*
Endoluminal circumference, µm 166 (157–188) 188 (182–201) 0.018*
External vessel diameter, µm 80 (72–86) 77 (70–85) 0.68
Mesothelial cell coverage (0–6) 3.5 (0–4.3) 3.0 (1.5–6.0) 0.54
Submesothelial thickness, µm 680 (368–920) 480 (332–616) 0.050*
Total microvessel density, /mm2 53.0 (33–235) 246 (146–420) 0.012*
Blood vessel density, /mm2* 38 (27–228) 237 (124–366) 0.012*
Lymphatic vessel density, /mm2* 10 (6.3–16.7) 23 (14.5–47.1) 5.3×103*
Blood vessel end. surface area, µm2/µm3* 4.9 (3–13) 11.3 (10–20) 9.8×102*
Lym. endothelial surface area, µm2/µm3* 1.8 (1.3–4.9) 2.5 (1.2–4.1) 0.87 
Lymphatic vessel perimeter, µm 146 (96–196) 99 (41–125) 0.023*
EMT [% pos. pat] 50% 10% 0.14†
ASMA positive [% patients] 20% 50% 0.34†
ASMA [/mm2 in pos. patients] 60 (51–68) 29 (12–43) 0.092
CD45 positive [% patients] 50% 50% 0.99†
CD45 [/mm2 in positive patients] 8 (4–9) 29 (20–51) 0.014*
CD68 positive [% patients] 50% 60% 0.99†
CD68 [/mm2 in positive patients] 8 (5–15) 25 (19–46) 0.021*
Mast cells [cells/mm2] 14 (13–17) 22 (14–33) 0.025*
Tryptase release/mast cell [pixel] 5829 (4396–8096) 12 556 (5090–13 510) 0.043*
Mann-Whitney test was used unless indicated by 
†. 3,4-DGE indicates 3,4-dideoxyglucosone-3-ene; ASMA, alpha smooth muscle actin; BMI, body mass index; EMT, epithelial-
mesenchymal transition; GDP, glucose degradation product; L/V, lumen/vessel; lym., lymphatic; n.a., not applicable; pat., patient; PD, 
peritoneal dialysis; and pos, positive.
*In each group, 1 patient with diffuse podoplanin staining was excluded from respective analysis.
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High-GDP Exposure Inhibits Submesothelial 
Angiogenesis and Immune Response and 
Enhances Fibrosis
GDP exposure was associated with suppression of 
omental arteriolar genes involved in endothelial cell 
migration/movement (Table II in the Data Supplement), 
Ingenuity Pathway Analysis demonstrated downregu-
lation of the angiogenesis pathway (activation Z score 
−0.8, P=5.0×10-5). In line with this, parietal perito-
neal vessel density was lower with high-GDP PD as 
compared to low-GDP PD. Peritoneal VEGF (vascu-
lar endothelial growth factor)-A was 50% lower with 
high-GDP than with low-GDP PD (Table VI in the Data 
Supplement), and correlated negatively with the indi-
vidual GDP and 3,4-DGE exposure (r=−0.51, P=0.024 
and r=−0.45, P=0.051) and with microvessel density 
(r=0.44, P=0.050). IL-17 abundance, a recently pro-
posed mediator of peritoneal angiogenesis via VEGF,24 
was 3.8-fold lower with high-GDP PD and corre-
lated with the GDP and 3,4-DGE exposure (r=−0.54, 
P=0.021 and r=−0.43, P=0.073), with microvessel den-
sity (r=0.46, P=0.043) and in the low-GDP group with 
VEGF-A abundance (r=0.66, P=0.031).
Omental arteriolar GDP exposure also downregu-
lated immune cell trafficking and cell-mediated immune 
response (Table II in the Data Supplement). In line with 
this, peritoneal immune cell infiltration was low with high-
GDP PD, that is, few CD45 leukocytes, CD68 macro-
phages, and mast cells were present; tryptase release 
per mast cell was lower compared with low-GDP PD 
(Table 2). Total submesothelial tryptase inversely corre-
lated with GDP exposure (r=−0.47, P=0.032) and with 
VEGF-A abundance (r=0.39, P=0.089).
IL-33, which has been suggested to exert tissue-
protective and antifibrotic actions,25 and IL-6 inversely 
correlated with the increased submesothelial thickness 
(r=−0.84, P=0.011; r=−0.75, P=0.0044) but not with 
inflammatory cell infiltration. IL-33 receptor ST2 (sup-
pressor of tumorigenicity 2) was not statistically differ-
ent. EMT (epithelial-mesenchymal transition) cells, a key 
component of submesothelial fibrosis development,26 
were detected in 5 out of the 10 patients in the high- 
and 1 out of 10 patients in the low-GDP group (Table 2).
In Vitro Validation of Key Arteriolar Findings
Human umbilical arterial endothelial cells were treated 
for 24 hours with increasing doses of 3,4-DGE as 
present in high-GDP PD fluids. 3,4-DGE dose-
dependently reduced perinuclear lamin-A/C. Similar 
findings were obtained for human umbilical vein endo-
thelial cells treated for 24 hours and for 5 hours per 
day over 3 and 7 consecutive days with increasing 
doses of 3,4-DGE (Figure II in the Data Supplement). 
In the same direction, increasing doses of 3,4-DGE 
resulted in upregulation of pSMAD2/3 and a progres-
sive disruption of membrane ZO-1. Respective func-
tional studies demonstrated a dose-dependent decline 
in transendothelial electrical resistance and increased 
permeability for 4 kDa dextran with 5 to 20 µmol/L of 
3,4-DGE exposure (Figure 6).
Table 3. Parietal Arteriolar Protein Regulation
 High-GDP PD (n=10) Low-GDP PD (n=10)
P value (Mann-
Whitney test)
AGE [% pos. area] 9.4 (6.9–15.1) 5.5 (3.2–8.8) 0.062
RAGE [% pos. area] 17.6 (9.3–27.6) 8.8 (5.4–18.1) 0.11
Lamin-A/C [% pos. area] 9.5 (7.5–10.7) 13.0 (8.6–15.0) 0.049
Casp3 [% pos. area] 10.0 (8.8–13.6) 5.6 (2.5–9.7) 0.017
p16 [% pos. area] 14.0 (8.5–31.8) 8.3 (2.7–16.4) 0.065
IL-33 [% pos. area] 7.5 (6.8–9.9) 6.3 (4.7–11.5) 0.19
ST2 [% pos. area] 29.4 (22.1–35.1) 20.9 (18.6–28.0) 0.13
pSMAD2/3 [% pos. area] 15.7 (11.1–25.2) 11.2 (5.9–17.3) 0.062
IL-6 [% pos. area] 21.9 (13.3–30.4) 11.2 (3.9–19.5) 0.068
Ki67 [% pos. area] 3.6 (1.8–7.1) 2.5 (0.6–8.4) 0.51
VEGF-A [% pos. area] 5.9 (3.3–7.3) 6.1 (4.5–10.1) 0.59
Myo-1B [% pos. area] 14.7 (8.6–20.5) 7.7 (4.6–11.7) 0.018
PFN1 [% pos. area] 9.6 (5.6–11.3) 10.3 (6.0–13.5) 0.59
ZO-1 [% pos. area] 44.8 (39.4–51.8) 37.8 (35.3–44.5) 0.16
CLDN1 [% pos. area] 6.7 (5.4–9.1) 7.4 (4.4–9.4) 0.68
AGE indicates advanced glycation end products; Casp3, caspase-3; CLDN, claudin-1; GDP, glucose degradation prod-
uct; IL, interleukin; Myo1B, myosin1B; PD, peritoneal dialysis; PFN1, profilin 1; pos., positive; pSMAD, phosphorylated 
SMAD; RAGE, receptor for advanced glycation end products; ST2, suppressor of tumorigenicity 2; VEGF, vascular endo-
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DISCUSSION
Reactive metabolites play a key role in the aging process 
and aging-related disorders including neurodegenera-
tive and psychiatric diseases.27,28 Long-term complica-
tions of diabetes mellitus are driven by reactive glucose 
metabolites.29,30 Reactive metabolites also accumulate 
in patients with CKD and normal glucose homeostasis; 
their impact on patient outcome, however, is uncertain.31 
With regards to the peritoneal dialysis treatment modality, 
it is still controversial whether the high concentrations 
of reactive metabolites present in conventional PD flu-
ids, such as the highly reactive dicarbonyl compounds 
methylglyoxal and 3,4-DGE, impact PD patient outcome. 
High-GDP PD fluids are still widely used since improved 
outcomes with the use of low-GDP fluids have not been 
demonstrated to date.9,32 Here, we provide evidence that 
GDP play a fundamental role in arteriolar remodeling.
PD fluids exert metabolic tissue stress, which declines 
with penetration depth.33 The omental arterioles analyzed 
Figure 5. Endothelial ZO-1 (zonula occludens-1) clustering is modified by high–glucose degradation products (H-GDP) 
peritoneal dialysis (PD).
A, Single-molecule localization microscopy quantification of ZO-1 clustering within 100 nm distance in parietal peritoneal arteriolar tissue sections 
of low-GDP (L-GDP)–treated and H-GDP–treated patients (n=3 per group). The representative images on the right give an overview of single 
arterioles (inset in the upper right corners) and single ZO-1 molecule visualization with H- (upper image) and L-GDP PD (lower image), scale 
bar=10 µm. Data are presented as median (interquartile range [IQR]), 2-way ANOVA followed by Holm-Sidak test for multiple comparison was 
applied. Letters indicate significant differences between the groups, individual P values are listed in Table VII in the Data Supplement. B, The 
respective frequencies of the distances between single ZO-1 molecules, (C) the membrane-bound ZO-1 molecules per nm2, n=25. In B and C, 
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Figure 6. 3,4-dideoxyglucosone-3-ene (3,4-DGE) suppresses lamin-A/C, induces phosphorylation of SMAD2/3, disrupts 
membrane ZO-1 (zonula occludens-1), and increases endothelial monolayer permeability.
Human umbilical arterial endothelial cells (HUAEC) were treated with 3,4-DGE at concentrations as present in high–glucose degradation products 
(GDP) fluids for 24 h. A, 3,4-DGE dose-dependently decreases lamin-A/C. A representative IF staining is given on the left side, Image-J quantification 
in the middle (n=3), a representative WB on the lower right, and respective quantification of the WB on the upper right (n=6). B, Phosphorylation 
of SMAD2/3 is increased (n=3). C, Total endothelial ZO-1 is unchanged (n=3), cell membrane ZO-1 is disintegrated (n=10). A–C, Analyzed by 
nonparametric Kruskal-Wallis test). Scale bars=50 µm. D, In transwells, HUAEC paracellular ionic permeability (transendothelial electric resistance, 
presented as relative change to medium control, n=6), and 4, 10, and 70 kDa dextran permeabilities in response to increasing concentrations of 3,4-
DGE are given (n=6), 2-way ANOVA followed by comparison of treatment vs control group with Holm-Sidak correction was applied. A.U. indicates 
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in our study were surrounded by at least 1 mm of fat 
tissue and should reflect systemic effects of the PD 
fluids, that is, the specific effects of absorbed GDP. 
90% of the osmotic gradient exerted by PD fluids dis-
sipates within the superficial 400 µm of the peritoneal 
membrane.33 They were carefully selected from young 
pediatric patients, devoid of confounding lifestyle-related 
factors and with underlying diseases not affecting vascu-
lar integrity. Within the 3 cohorts studied, there were no 
statistical differences in anthropometric and biochemical 
findings and regarding the PD prescriptions in the 2 PD 
cohorts, except for the PD-associated GDP load. Thus, 
despite the limited number of patients with high-GDP 
fluid usage available for analysis a highly sensitive analy-
sis could be accomplished. Our cross-omics approach 
leverages specific advantages of the 2 different omics 
methods—transcriptome analysis allows sensitive detec-
tion of molecular perturbations with high coverage of the 
expressed genome, whereas proteome analysis detects 
biological players at the effector level.
The salient findings of our open omics approach in 
omental arterioles exposed to high concentrations of 
GDP are the upregulation of genes and proteins involved 
in cell death and apoptosis and deactivation of cell viabil-
ity and survival, cytoskeleton and junction organization, 
and immune response biofunctions. These transcrip-
tional perturbations were evident in comparison to both 
patients before start of dialysis and those on low-GDP 
PD. Exposure to low-GDP fluids was associated with 
only minor transcriptional changes in omental arterioles 
compared to the pre-PD status.
The GDP-related alterations observed in omen-
tal arterioles were quantitatively reproduced in parietal 
peritoneal arterioles, which were also exposed to direct 
effects of PD fluids, that is, increased glucose concen-
trations. More lumen narrowing and endothelial cell loss 
were observed with dialytic GDP exposure. The exter-
nal circumference was not statistically different in both 
groups, while the internal circumference was reduced in 
patients exposed to GDP, that is, the lumen smaller with 
the intima thickness being significantly higher in high-
GDP treated patients. All tissue samples were taken 
during stable cardiocirculatory conditions under general 
anesthesia; some impact of the vascular tone on these 
findings, however, cannot entirely be excluded.
The dialytic glucose load was not statistically dif-
ferent with high- versus low-GDP fluid usage, dialytic 
GDP load, however, was 4- to 12-fold higher. GDP are 
not locally retained or metabolized to a major extent34 
but rapidly absorbed, bind nonenzymatically to proteins 
and lipids, and form AGE. GDP are potent glycating 
agents; for instance, methylglyoxal is up to 50 000× 
more reactive than glucose.35 Circulating AGE concen-
trations are 20% higher with high-GDP fluid usage.4,5 In 
the arterioles studied here, AGE abundance was 2- to 
3-fold increased.
In vitro, GDP induces apoptosis of mesothelial cells 
in the presence of inflammatory cytokines.36 Adminis-
tration of methylglyoxal in rats leads to vascular AGE 
deposition, endothelial cell loss, and lumen narrowing.37 
AGE induce extracellular protein crosslinking, reduce 
vascular elasticity, bind to RAGE, and activate proin-
flammatory NF (nuclear factor)-κB and apoptosis.38,39 
We now demonstrate in humans that GDP activate 
apoptotic pathways in omental and parietal arteriolar 
endothelial cells, with downregulation of lamin-A/C and 
upregulation of caspase-3. Downregulation of lamin-
A/C was evident on transcriptome and proteome level, in 
parietal arteriolar immunohistochemical quantification, 
and upon 3,4-DGE exposure in human umbilical arterial 
endothelial cells and human umbilical vein endothelial 
cells in vitro. Lamin-A/C stabilize the cell nucleus, are 
targeted by caspases in the apoptotic process,40 and 
are essentially involved in premature aging.41
Another mechanism of vasculopathy disclosed by the 
omics analyses of arterioles relates to the disorganiza-
tion of the cytoskeleton and cell-cell junctions. ZO-1, an 
intracellular scaffold protein bridging tight junction clau-
dins to the actin cytoskeleton,42,43 was not statistically 
different in abundance in the arterioles with low- and 
high-GDP exposure. Since junction function depends on 
spatial molecule distribution, we for the first time applied 
single-molecule localization microscopy in tissue and 
demonstrate disruption of the spatial clustering of ZO-1 
in the endothelial membrane regions by GDP; the ran-
domness of ZO-1 distribution in the surrounding areas 
increased. The GDP-related endothelial ZO-1 disruption 
was reconfirmed in endothelial cells in vitro and resulted 
in increased paracellular ionic and dextran permeability, 
that is, disruption of the arterial endothelial cell barrier 
integrity. The sealing junction CLDN1 was not affected 
in abundance by GDP but was inversely related with the 
degree of arteriolar lumen narrowing, again suggesting 
sealing junction dysfunction as demonstrated for ZO-1.
Myo-1B is an actin depolymerase regulating actin 
dynamics in vivo nearby cellular membranes44 and coor-
dinating receptor signaling by arranging the cytoskel-
eton.45 We demonstrate Myo-1B upregulation with GDP 
exposure in the cross-omics analysis in omental arteri-
oles and in parietal arterioles. Altogether, our stepwise 
approach demonstrates disruption of the endothelial 
barrier integrity by GDP on several levels as an early 
event in the multifactorial, gradually progressive devel-
opment of vasculopathy.22
Next to the arteriolar effects of GDP, our studies 
provide detailed information regarding the effect of 
GDP on the parietal peritoneum. As previously reported 
by our group, exposure to low-GDP PD fluids induced 
VEGF-A and angiogenesis and marked inflammatory 
cell infiltration.46 We now demonstrate that exposure 
to PD fluids with high-GDP content mitigated peri-
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blood leukocytes, macrophages, and mast cells; trypt-
ase release was reduced. Peritoneal VEGF-A, IL-6, 
IL-17, and IL-33 signaling were substantially reduced. 
Thus, the peritoneal findings mirror the deactivation 
of cellular and humoral inflammatory cascades in the 
omental arterioles exerted by GDP. This observation is 
supported by experimental studies. Methylglyoxal pro-
motes degradation of hypoxia-inducible factor-1α and 
inhibits angiogenesis via VEGF.47 Glyoxylase-1 overex-
pression in mice reduces tissue methylglyoxal con-
centrations and scar size after coronary artery ligation; 
cardiac vessel density increases.48 The link between 
peritoneal IL-17, VEGF induction, and angiogenesis 
has recently been established24 and is supported here 
by the correlation of peritoneal IL-17 with VEGF abun-
dance and microvessel density. Activated mast cells 
induce angiogenesis via release of growth factors, 
interleukins, and matrix metalloproteinases,49,50 find-
ings which are now underpinned by the correlation of 
peritoneal VEGF-A abundance with tryptase released 
from activated mast cells.
The GDP-driven induction of multiple pathways 
involved in vasculopathy as demonstrated in omental 
arterioles and the advanced lumen narrowing develop-
ing in parietal arterioles concomitantly exposed to high-
GDP and glucose concentrations is of great concern in 
view of the exceedingly high cardiovascular disease risk 
of patients with advanced CKD.2,51,52 Small arteries and 
precapillary arterioles control peripheral resistance and 
microcirculation; thus, our findings are of clinical relevance 
and mandate treatment strategies designed to reduce 
systemic GDP load, such as the application of low-GDP 
dialysis fluids in patients on PD. Innovative strategies may 
comprise targeting of endothelial barrier dysfunction, for 
example, by supplementation of alanyl glutamine53,54 and 
interventions improving GDP detoxification55 or adminis-
tration of scavengers, such as histidine-containing pep-
tides resistant to degradation by carnosinase-1.56
Limitations of this study consisted of the low number 
of omental tissues available from children on high-GDP 
PD treatment, fulfilling the rigorous inclusion criteria and 
tissue quality criteria. The untargeted multiomics dis-
covery analyses identified distinct arteriolar pathways 
and were followed by enrichment analysis of biologi-
cal processes applying FDR and Benjamini-Hochberg 
correction. These processes were subsequently vali-
dated in different tissues with different methodological 
approaches and targets. Still, false associations cannot 
entirely be excluded. The quantitative validation of the 
transcriptome and proteome could not be obtained in 
the same tissues with reasonable power, but in arterioles 
simultaneously exposed to high glucose concentrations. 
Since the dialytic glucose load was not statistically dif-
ferent in patients treated with low- and high-GDP fluids, 
the findings could not only be validated but extended to 
a model with similarities to patients with diabetes and 
with significant endothelial cell loss and advanced lumen 
narrowing. Within the purpose of this study, we analyzed 
the most striking arteriolar omics findings. The com-
prehensive arteriolar gene and protein data sets repre-
sent a unique source of data, suggesting several other 
pathomechanisms of interest, for example, suppression 
of radical scavenging, and lipid and carbohydrate metab-
olism perturbation, which deserve extended studies.
In conclusion, our comprehensive studies demon-
strate major GDP-induced pathomechanisms of arterio-
lar remodeling in children on chronic PD. These findings 
question the use of high-GDP PD fluids and should redi-
rect the focus of research and therapeutic interventions 
to targeting GDP overload in CKD, improvement of GDP 
clearance, and improving vascular endothelial integrity.
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